• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Researchers develop insulin-producing artificial beta cells

December 9, 2016 By Sarah Faulkner

Researchers develop insulin-producing artificial beta cells

Researchers from ETH Zurich have developed artificial beta cells that can measure blood glucose concentration and respond by producing insulin. The team’s work was published this week in Science. 

The ETH researchers used the natural glucose transport proteins and potassium channels found in the membrane of human kidney cells and modified them with a voltage-dependent calcium channel, a gene to produce insulin and a hormone that helps to regulate blood sugar levels, GLP-1. Early tests of the cells in mice with diabetes were promising, as the modified human kidney cells worked for 3 weeks, according to the team. “They worked better and for longer than any solution achieved anywhere in the world so far,” lead researcher Professor Martin Fussenegger said in prepared remarks.

Glucose is carried into the cell from the bloodstream via the cells’ natural glucose transport protein. When the cell detects that the blood sugar level is too high, the potassium channels close, altering the voltage distribution at the cell membrane and opening the calcium channel. Insulin and GLP-1 production is triggered when calcium flows into the artificial beta cells.

The team used a computer model to predict cellular behavior and then confirmed the theoretical results with experimental data. “The data from the experiments and the values calculated using the models were almost identical,” Fussenegger said.

It could take a while before the artificial beta cells are ready to hit the market, Fussenegger explained. “If our cells clear all the hurdles, they could reach the market in 10 years,” he said.

Filed Under: Diabetes, Featured, Research & Development, Stem Cells Tagged With: ETH Zurich

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS